Residual Schizophrenia

Residual-type schizophrenia is characterized by a past history of a least one episode of schizophrenia, but the person will currently have no positive symptoms (delusions, hallucinations, disorganized speech or behavior).

 

Cluster Number:
Wiki Number: PW186
Diagnosis: Residual Schizophrenia
US Patients:
World Patients:
Sex Ratio:
Age Onset:
Brain Area:
Symptoms: Schizophrenia’s negative (but milder) symptoms primarily: isolating from others, blunted emotions, losing interest in life.
Progression: Positive symptoms: hallucinations and putting thoughts together; cognitive symptoms: problems with memory and attention.
Causes: Positive symptoms also include acting inappropriately, talking in a strange made-up language. “Residual” must follow 6 months of
Medications: None listed.// positive schizophrenic symptoms. “Residual” is like “after-glow.”
Therapies: None listed.

4 CURRENT ARTICLES
FROM PUBMED

The world-wide medical research
reports chosen for each diagnosis 

Clicking each title opens the
PubMed article’s summary-abstract.

  • Color painting predicts clinical symptoms in chronic schizophrenia patients via deep learning
    by Hui Shen on October 23, 2021

    CONCLUSION: In conclusion, the deep learning paradigm showed the large potential to discriminate schizophrenia patients from HCs based on color paintings. Besides, this color painting-based paradigm can effectively predict clinical symptom severity for chronic schizophrenia patients. The color paintings by schizophrenia patients show potential as a tool for clinical diagnosis and prognosis. These findings show potential as a tool for clinical diagnosis and prognosis among schizophrenia patients.

  • Cognitive Behavioral Therapy in Treatment of Schizophrenia
    by Ayşegül Kart on October 18, 2021

    Schizophrenia is a heterogeneous disorder that affects behavioral, affective, and cognitive domains and consists of positive and negative psychotic symptoms. Antipsychotic therapy is the first-line treatment for schizophrenia. However, treatment adherence levels are low. Even if there is good treatment compliance, residual symptoms and treatment resistance can be seen. As a result, recent schizophrenia treatment guidelines suggest Cognitive Behavioral Therapy (CBT) as adjunctive to antipsychotic...

  • Adolescent cannabis use and adult psychoticism: A longitudinal co-twin control analysis using data from two cohorts
    by Jonathan D Schaefer on September 23, 2021

    Observational studies have repeatedly linked cannabis use and increased risk of psychosis. We sought to clarify whether this association reflects a causal effect of cannabis exposure or residual confounding. We analyzed data from two cohorts of twins who completed repeated, prospective measures of cannabis use (N = 1544) and cannabis use disorder symptoms (N = 1458) in adolescence and a dimensional measure of psychosis-proneness (the Personality Inventory for DSM-5 Psychoticism scale) in...

  • Pharmaco-Magnetic Resonance as a Tool for Monitoring the Medication-Related Effects in the Brain May Provide Potential Biomarkers for Psychotic Disorders
    by Katrin Aryutova on September 10, 2021

    The neurodegenerative and neurodevelopmental hypotheses represent the basic etiological framework for the origin of schizophrenia. Additionally, the dopamine hypothesis, adopted more than two decades ago, has repeatedly asserted the position of dopamine as a pathobiochemical substrate through the action of psychostimulants and neuroleptics on the mesolimbic and mesocortical systems, giving insight into the origin of positive and negative schizophrenic symptoms. Meanwhile, cognitive impairments...